Celularity Inc - מכפיל שווי פעילות להכנסות CELU

The EV/Sales ratio allows for a valuation of Celularity Inc. (CELU) through the lens of sales, where the metric has reached 4522.23. This trend reflects the implementation of regenerative biomaterials and the development of biobanking. Management is focusing on the monetization of placental cells for medical use. The current strategic vector relies on optimizing product output and licensing technologies to third-party partners.
Celularity Inc. - פילוחים אנליטיים ומדדי מפתח (CELU)

This indicator determines the investment attractiveness of Celularity Inc. (CELU) by comparing Enterprise Value (EV) to annual sales, which neutralizes the impact of debt load on the valuation. By analyzing the EV/Sales trajectory, an investor can see the market value of assets relative to revenue, which for Celularity Inc. is supported by strategic partnerships with oncology centers and the licensing of innovative cell technologies.